Seppala, L. J.
,
van der Velde, N.
Masud, T.
Blain, H.
Petrovic, M.
van der Cammen, T. J.
Szczerbińska, K.
Hartikainen, S.
Kenny, R. A.
Ryg, J.
Eklund, P.
Topinková, E.
Mair, A.
Laflamme, L.
Thaler, H.
Bahat, G.
Gutiérrez-Valencia, M.
Caballero-Mora, MA
Landi, F.
Emmelot-Vonk, M. H.
Cherubini, A.
Baeyens, J. P.
Correa-Pérez, A.
Gudmundsson, A.
Marengoni, A.
O’Mahony, D.
Parekh, N.
Pisa, F. E.
Rajkumar, C.
Wehling, M.
Ziere, G.
,
Funding for this research was provided by:
Amsterdam University Fund
Article History
First Online: 11 February 2019
Compliance with Ethical Standards
:
: This study was supported by the Clementine Brigitta Maria Dalderup fund, which is an Amsterdam University fund. The sponsor played no part in the design or preparation of this paper.
: Martin Wehling was employed by AstraZeneca R&D, Mölndal, as Director of Discovery Medicine (= translational medicine) from 2004 to 2006 while on sabbatical leave from his professorship at the University of Heidelberg. After returning to this position in January 2007, he received lecturing and consulting fees from Bristol Myers, Bayer, LEO, Boehringer-Ingelheim, Mundipharma, Novartis, Pfizer, Roche, AstraZeneca, Allergan, Polyphor, Helsinn, Sanofi-Aventis, Shire, Otsuka, Lilly, Berlin-Chemie, and Novo-Nordisk. The work of Eva Topinkova was partially supported by grant no. 16-33463A from the Czech Ministry of Health, Czech Republic. LJS, NvdV, TM, HB, MP, TJvdC, KS, SH, RAK, JR, PE, AMair, LL, HT, GB, MG-V, MAC-M, FL, MHE-V, AC, JPB, AC-P, AG, AM, DO, NP, FEP, CR, GZ have no conflicts of interest that are directly relevant to the content of this article.